ResMed’s Astral Life Support Ventilator Now Has AutoEPAP in U.S.
Other upgrades include easy interface switching and program naming to improve ease of use
SAN DIEGO--(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD), a global leader in cloud-connected respiratory care devices, today announced key upgrades to its Astral life support ventilators, including Optional AutoEPAP in iVAPS for U.S. patients, a high-demand therapy option.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180827005110/en/
ResMed's Astral ventilator (Photo: Business Wire)
What is AutoEPAP?
AutoEPAP (automatic expiratory positive airway pressure) automatically adjusts a patient’s expiratory pressure in response to flow limitations or obstruction of the upper airway.
AutoEPAP is now available in the United States, and already in use in other markets. It’s an option when in Astral’s iVAPS (intelligent Volume-Assured Pressure Support) mode that automatically adapts to a patient’s changing pressure needs as their respiratory disease progresses.
Other upgrades
In addition to AutoEPAP, Astral users worldwide can now:
- Easily change interfaces: Patients can easily change between a mouthpiece and a full face, nasal or pillows mask from a single limb circuit.
- Customize program names: Clinicians can now name programs on a patient’s Astral device for fast, easy access.
“These significant upgrades make Astral one of the most advanced life support ventilators on the market,” said Richie McHale, president of ResMed’s Respiratory Care business. “It’s already proven to stabilize ventilation in significantly fewer breaths than its leading competitor,1 and today’s innovations offer greater ease of use and even more peace of mind to patients across a wide range of respiratory diseases than ever before.”
About ResMed
ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com
1 Diesem Ryan. Astral/Trilogy iVAPS/AVAPS Comparison. Valley Inspired Products 2016; 16011.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180827005110/en/
ResMed
For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
or
For
investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
Source: ResMed
Released August 27, 2018